Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Lineage Cell Therapeutics Inc's Business Segments
Lineage Cell Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
3
Largest Segment
Collaboration Revenues
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Collaboration Revenues0%
- Upfront License Fees99%
- Royalties license and other revenues25.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration Revenues | $ 3 | - |
| Upfront License Fees | $ 1 | 99% |
| Royalties license and other revenues | $ 0 | 25.8% |
Revenue by Product & Service Category - FY
- Collaboration Revenues91.3%
- Upfront License Fees49.9%
- Event Based Milestones and Other Collaborative Revenue41.4%
- Royalties license and other revenues8.7%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration Revenues | $ 2 | 91.3% |
| Upfront License Fees | $ 1 | 49.9% |
| Event Based Milestones and Other Collaborative Revenue | $ 1 | 41.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Lineage Cell Therapeutics Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Collaboration Revenues0%
- Upfront License Fees99%
- Royalties license and other revenues25.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration Revenues | $ 3 | - |
| Upfront License Fees | $ 1 | 99% |
| Royalties license and other revenues | $ 0 | 25.8% |
Description of Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company that is focused on developing and commercializing innovative cell-based therapies for the treatment of various diseases and medical conditions. The company is headquartered in Carlsbad, California and was founded in 1990.
One of the primary areas of focus for Lineage Cell Therapeutics is cellular therapy, which involves using stem cells and progenitor cells to regenerate and repair damaged tissues and organs. The company's proprietary technology platform, called VAC2, allows for the selective expansion of specific populations of immune cells for use in cancer immunotherapy.
Lineage Cell Therapeutics' lead product candidate is OpRegen, which is being developed for the treatment of dry age-related macular degeneration (AMD), a leading cause of blindness. OpRegen is an investigational therapy that uses retinal pigment epithelium (RPE) cells derived from human pluripotent stem cells to replace damaged cells in the retina. The company has completed a Phase 1/2a clinical trial for OpRegen and is currently conducting a Phase 2a clinical trial to further evaluate its safety and efficacy.
In addition to OpRegen, Lineage Cell Therapeutics has a number of other product candidates in its pipeline. For example, the company is developing a therapy called OPC1, which uses oligodendrocyte progenitor cells (OPCs) derived from human pluripotent stem cells to treat spinal cord injuries. OPC1 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and is currently being evaluated in a Phase 1/2a clinical trial.
Lineage Cell Therapeutics is also exploring the potential of its cell therapy technology in other areas, including cancer immunotherapy and neurological conditions. The company's VAC2 platform is being used to develop cancer vaccines that stimulate the immune system to target and destroy cancer cells. Lineage Cell Therapeutics is currently conducting preclinical studies and expects to initiate clinical trials for its cancer immunotherapy programs in the future.
Overall, Lineage Cell Therapeutics Inc. is a biotechnology company that is at the forefront of developing and commercializing cell-based therapies for a wide range of diseases and medical conditions. The company's innovative technology platform and promising product candidates position it well for potential success in the emerging field of regenerative medicine.
One of the primary areas of focus for Lineage Cell Therapeutics is cellular therapy, which involves using stem cells and progenitor cells to regenerate and repair damaged tissues and organs. The company's proprietary technology platform, called VAC2, allows for the selective expansion of specific populations of immune cells for use in cancer immunotherapy.
Lineage Cell Therapeutics' lead product candidate is OpRegen, which is being developed for the treatment of dry age-related macular degeneration (AMD), a leading cause of blindness. OpRegen is an investigational therapy that uses retinal pigment epithelium (RPE) cells derived from human pluripotent stem cells to replace damaged cells in the retina. The company has completed a Phase 1/2a clinical trial for OpRegen and is currently conducting a Phase 2a clinical trial to further evaluate its safety and efficacy.
In addition to OpRegen, Lineage Cell Therapeutics has a number of other product candidates in its pipeline. For example, the company is developing a therapy called OPC1, which uses oligodendrocyte progenitor cells (OPCs) derived from human pluripotent stem cells to treat spinal cord injuries. OPC1 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and is currently being evaluated in a Phase 1/2a clinical trial.
Lineage Cell Therapeutics is also exploring the potential of its cell therapy technology in other areas, including cancer immunotherapy and neurological conditions. The company's VAC2 platform is being used to develop cancer vaccines that stimulate the immune system to target and destroy cancer cells. Lineage Cell Therapeutics is currently conducting preclinical studies and expects to initiate clinical trials for its cancer immunotherapy programs in the future.
Overall, Lineage Cell Therapeutics Inc. is a biotechnology company that is at the forefront of developing and commercializing cell-based therapies for a wide range of diseases and medical conditions. The company's innovative technology platform and promising product candidates position it well for potential success in the emerging field of regenerative medicine.
Lineage Cell Therapeutics Inc. is a pioneering clinical-stage biotechnology company engaged in the development and commercialization of advanced cellular therapies aimed at treating a variety of degenerative diseases. The company is focused on harnessing the power of stem cells and innovating therapeutic solutions that can address significant medical challenges. Their operations are structured across multiple segments, each designed to tackle specific therapeutic needs, and encompass a diverse portfolio of products and services. Below is an extensive overview of these segments, products, and services.
Segments
1. Therapeutic Programs:
- Retinal Diseases: This segment focuses on developing therapies for diseases that affect the retina, particularly age-related macular degeneration (AMD), which is a leading cause of vision loss in older adults. The programs aim to restore vision by replacing or repairing damaged retinal cells.
- Neurological Disorders: Lineage is developing therapies targeting neurological conditions, including spinal cord injuries. These programs leverage cellular therapies to promote nerve regeneration and support recovery in patients.
- Cancer: The oncology segment includes innovative immunotherapy approaches designed to activate the body’s immune system to target and destroy cancer cells. The emphasis is on developing both dendritic cell-based therapies and other immune-modulating strategies.
- Transplant Support: This program is focused on providing therapeutic solutions that facilitate the success of stem cell transplants by enhancing immune compatibility and reducing the risk of rejection, thereby improving patient outcomes.
2. Cell-Based Medicines:
- Lineage specializes in manufacturing and developing cell-based therapies that utilize human stem cells and progenitor cells. These therapies are aimed at repairing or regenerating damaged tissues and organs, offering potential treatment avenues for health issues that currently lack effective solutions.
Products and Services
1. OpRegen:
- OpRegen is the flagship product candidate targeting retinal degenerative diseases, specifically AMD. This cell-based therapy involves the transplantation of retinal progenitor cells that aim to replace the damaged retinal cells, with the goal of restoring or improving patient vision. This innovative approach addresses a critical unmet medical need in the treatment of progressive retinal diseases.
2. OPC1:
- OPC1 is a groundbreaking therapeutic candidate designed for spinal cord injury. Utilizing oligodendrocyte progenitor cells, OPC1 focuses on remyelination—all crucial for promoting nerve regeneration. Clinical trials aim to assess its ability to improve functional outcomes for individuals suffering from spinal cord injuries, marking a significant step in the field of neurology.
3. VAC2:
- VAC2 is an allogeneic dendritic cell immunotherapy targeted at non-small cell lung cancer (NSCLC). By leveraging dendritic cells to activate the immune response, VAC2 aims to enhance the body’s ability to detect and attack cancer cells, potentially leading to improved survival rates and better quality of life for patients undergoing treatment for this aggressive cancer type.
4. VAC1-DC-TC:
- The VAC1-DC-TC platform focuses on treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). This therapy employs dendritic cells to help the immune system recognize and target malignant cells, aiming to increase survival rates and reduce the likelihood of relapse in patients who have undergone stem cell transplantation. This innovative approach represents Lineage’s commitment to improving outcomes in hematologic malignancies.
5. Research and Development Services:
- In addition to its proprietary therapies, Lineage Cell Therapeutics extends its expertise in cellular therapies by providing research and development services. These services are designed to facilitate collaborations with other biotechnology firms, academic institutions, and organizations striving to advance innovative treatments through shared knowledge and complementary technologies.
Conclusion
Lineage Cell Therapeutics Inc. is at the forefront of cellular therapy innovation, actively working to develop and commercialize treatments that address various degenerative diseases. With an extensive range of therapeutic programs, a focus on cell-based medicines, and a commitment to advancing medical science through research and development collaborations, the company aims to provide transformative solutions for patients and healthcare providers alike. Their distinct product candidates are set to play a crucial role in shaping the future landscape of regenerative medicine and oncology.
Segments
1. Therapeutic Programs:
- Retinal Diseases: This segment focuses on developing therapies for diseases that affect the retina, particularly age-related macular degeneration (AMD), which is a leading cause of vision loss in older adults. The programs aim to restore vision by replacing or repairing damaged retinal cells.
- Neurological Disorders: Lineage is developing therapies targeting neurological conditions, including spinal cord injuries. These programs leverage cellular therapies to promote nerve regeneration and support recovery in patients.
- Cancer: The oncology segment includes innovative immunotherapy approaches designed to activate the body’s immune system to target and destroy cancer cells. The emphasis is on developing both dendritic cell-based therapies and other immune-modulating strategies.
- Transplant Support: This program is focused on providing therapeutic solutions that facilitate the success of stem cell transplants by enhancing immune compatibility and reducing the risk of rejection, thereby improving patient outcomes.
2. Cell-Based Medicines:
- Lineage specializes in manufacturing and developing cell-based therapies that utilize human stem cells and progenitor cells. These therapies are aimed at repairing or regenerating damaged tissues and organs, offering potential treatment avenues for health issues that currently lack effective solutions.
Products and Services
1. OpRegen:
- OpRegen is the flagship product candidate targeting retinal degenerative diseases, specifically AMD. This cell-based therapy involves the transplantation of retinal progenitor cells that aim to replace the damaged retinal cells, with the goal of restoring or improving patient vision. This innovative approach addresses a critical unmet medical need in the treatment of progressive retinal diseases.
2. OPC1:
- OPC1 is a groundbreaking therapeutic candidate designed for spinal cord injury. Utilizing oligodendrocyte progenitor cells, OPC1 focuses on remyelination—all crucial for promoting nerve regeneration. Clinical trials aim to assess its ability to improve functional outcomes for individuals suffering from spinal cord injuries, marking a significant step in the field of neurology.
3. VAC2:
- VAC2 is an allogeneic dendritic cell immunotherapy targeted at non-small cell lung cancer (NSCLC). By leveraging dendritic cells to activate the immune response, VAC2 aims to enhance the body’s ability to detect and attack cancer cells, potentially leading to improved survival rates and better quality of life for patients undergoing treatment for this aggressive cancer type.
4. VAC1-DC-TC:
- The VAC1-DC-TC platform focuses on treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). This therapy employs dendritic cells to help the immune system recognize and target malignant cells, aiming to increase survival rates and reduce the likelihood of relapse in patients who have undergone stem cell transplantation. This innovative approach represents Lineage’s commitment to improving outcomes in hematologic malignancies.
5. Research and Development Services:
- In addition to its proprietary therapies, Lineage Cell Therapeutics extends its expertise in cellular therapies by providing research and development services. These services are designed to facilitate collaborations with other biotechnology firms, academic institutions, and organizations striving to advance innovative treatments through shared knowledge and complementary technologies.
Conclusion
Lineage Cell Therapeutics Inc. is at the forefront of cellular therapy innovation, actively working to develop and commercialize treatments that address various degenerative diseases. With an extensive range of therapeutic programs, a focus on cell-based medicines, and a commitment to advancing medical science through research and development collaborations, the company aims to provide transformative solutions for patients and healthcare providers alike. Their distinct product candidates are set to play a crucial role in shaping the future landscape of regenerative medicine and oncology.